Business Summary: Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the research, development, and commercialization of biologic technologies for musculoskeletal care, with a focus on those supporting bone regeneration and bone growth. The Company's key product is MagnetOs, which is a synthetic bone graft technology available in multiple formats such as granules or putty. MagnetOs is designed to stimulate bone formation, including through mechanisms that engage the body’s immune response. The technology behind MagnetOs is associated with osteoimmunology, which involves immune-modulated bone healing. MagnetOs uses the proprietary NeedleGrip submicron surface technology, which supports bone growth by enhancing biological responses related to healing. It is indicated for use across the skeletal system and is positioned as a bone graft option for procedures involving various anatomical regions.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Kuros Biosciences AG revenues increased 72% to $146.1M. Net income before extraordinary items totaled $2.5M vs. loss of $4.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Impairment of assets decrease from $5.8M (expense) to $0K, Foreign Exchange Gain/LossNon-Business increase of 8% to $2.8M (income).